Abingdon Health Valuation Multiples

Discover Abingdon Health's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like NanoRepro, InspireMD, TELA Bio, Bioretec and more.

Abingdon Health Overview

About Abingdon Health

Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.


Founded

2008

HQ

United Kingdom

Employees

121

Financials (LTM)

Revenue: $17M
EBITDA: ($1M)

EV

$29M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Abingdon Health Financials

Abingdon Health reported last 12-month revenue of $17M and negative EBITDA of ($1M).

In the same LTM period, Abingdon Health generated ($1M) in EBITDA losses.

Revenue (LTM)


Abingdon Health P&L

In the most recent fiscal year, Abingdon Health reported revenue of $11M and EBITDA of ($3M).

Abingdon Health is unprofitable as of last fiscal year, with gross margin of 44%, EBITDA margin of (30%), and net margin of (40%).

See analyst estimates for Abingdon Health
LTMLast FY202320242025202620272028
Revenue$17M$11M$7M$10M$14M
Gross Profit-$5M$4M$5M$5M
Gross Margin-44%57%51%36%
EBITDA($1M)($3M)($3M)($2M)($3M)
EBITDA Margin(7%)(30%)(37%)(26%)(18%)
EBIT Margin(13%)(41%)(51%)(35%)(25%)
Net Profit-($4M)($3M)($3M)($5M)
Net Margin-(40%)(46%)(32%)(33%)

Financial data powered by Morningstar, Inc.

Abingdon Health Stock Performance

Abingdon Health has current market cap of $33M, and enterprise value of $29M.

Market Cap Evolution


Abingdon Health's stock price is $0.13.

Abingdon Health share price decreased by 3.5% in the last 30 days, and increased by 47.2% in the last year.

Abingdon Health has an EPS (earnings per share) of $-0.02.

See more trading valuation data for Abingdon Health
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$29M$33M-0.2%-3.5%16.9%47.2%$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Abingdon Health Valuation Multiples

Abingdon Health trades at 1.8x EV/Revenue multiple, and (23.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Abingdon Health

EV / Revenue (LTM)


Abingdon Health Financial Valuation Multiples

As of July 19, 2026, Abingdon Health has market cap of $33M and EV of $29M.

Abingdon Health has a P/E ratio of (7.3x).

LTMLast FY202320242025202620272028
EV/Revenue1.8x2.6x4.3x3.0x2.1x
EV/EBITDA(23.8x)(8.6x)(11.7x)(11.7x)(11.4x)
EV/EBIT(13.5x)(6.3x)(8.4x)(8.5x)(8.3x)
EV/Gross Profit-5.8x7.5x5.9x5.8x
P/E-(7.3x)(10.4x)(10.4x)(7.2x)
EV/FCF-(6.2x)(46.0x)(8.3x)(6.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Abingdon Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Abingdon Health Margins & Growth Rates

Abingdon Health grew revenue by 45% but EBITDA decreased by 61% in the last fiscal year.

In the most recent fiscal year, Abingdon Health reported gross margin of 44%, EBITDA margin of (30%), and net margin of (40%).

See estimated margins and future growth rates for Abingdon Health

Abingdon Health Margins

Last FY202420252026202720282029
Gross Margin44%51%36%-
EBITDA Margin(30%)(26%)(18%)(1%)
EBIT Margin(41%)(35%)(25%)(6%)
Net Margin(40%)(32%)(33%)-
FCF Margin(42%)(36%)(34%)-

Abingdon Health Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth45%43%42%33%
Gross Profit Growth-29%1%-
EBITDA Growth(61%)(0%)2%(92%)
EBIT Growth(51%)(2%)2%(67%)
Net Profit Growth-(1%)46%-
FCF Growth-454%35%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Abingdon Health Operational KPIs

Abingdon Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Abingdon Health's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Abingdon Health's Rule of X is 81% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Abingdon Health
LTMLast FY202320242025202620272028
Rule of 4016%32%---
Bessemer Rule of X50%81%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue-92%101%88%75%
Opex to Revenue-86%108%86%70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Abingdon Health Competitors

Abingdon Health competitors include NanoRepro, InspireMD, TELA Bio, Bioretec, Q-linea, Baird Medical Investment, BrainCool, Spirit Scientific Co, Cleo Diagnostics and OncoSil Medical.

Most Abingdon Health public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
NanoRepro4.6x1.3x(6.3x)(25.7x)
InspireMD(0.6x)(0.6x)0.1x0.1x
TELA Bio0.6x0.6x(1.6x)(1.7x)
Bioretec6.9x5.5x(3.0x)(3.3x)
Q-linea13.3x-(0.9x)-
Baird Medical Investment2.4x-(2.2x)-
BrainCool6.6x6.4x(8.1x)(9.8x)
Spirit Scientific Co2.8x-13.4x-

This data is available for Pro users. Sign up to see all Abingdon Health competitors and their valuation data.

Start Free Trial

Abingdon Health VC Funding History

Before going public, Abingdon Health raised $14M in total equity funding, across 4 rounds.

Last private valuation of Abingdon Health was $14M, after raising $4M in July 2016 from Imperial Innovations.


Abingdon Health Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-19SeedNPIF – Mercia Equity Finance$2M--
Jul-16SeedImperial Innovations$4M$14MAbingdon Health is a UK-based specialist medical diagnostics company founded in 2008 by Dr. Chris Hand and Dr. Brett Pollard to commercialise novel clinical diagnostics technologies. The company led a £3 million funding round on July 13, 2016, with Imperial Innovations investing £2 million alongside other private investors, resulting in Imperial holding a 28.6% stake post-investment. This implies a post-money valuation of approximately £10.49 million. Abingdon Health used the proceeds to acquire a controlling 50.1% stake in Molecular Vision, an Imperial Innovations portfolio company developing low-cost, point-of-care disposable diagnostic devices for kidney function, cardiovascular disease, and other applications. The funding also supported investments in other portfolio projects, including those from its joint venture with the University of Birmingham, Bioscience Ventures Ltd. Rebecca Todd from Imperial Innovations joined the board of Abingdon Health. Molecular Vision's technology enables simple on-site analysis across healthcare and other sectors, with Abingdon accelerating development by integrating complementary capabilities from its portfolio.
Jun-15SeedImperial Innovations$5M-Abingdon Health, a UK-based diagnostics firm, raised £3 million in a funding round led by Imperial Innovations with a £2 million investment, plus £1.02 million from private investors. The round occurred around mid-2015 to fund the acquisition of a 50.1% stake in Molecular Vision, another Imperial portfolio company, and investments in other projects including those from Bioscience Ventures, a joint venture with the University of Birmingham. Following the investment, Imperial Innovations held a 28.6% stake in Abingdon Health while retaining a 36.4% stake in Molecular Vision.
Oct-14Seed-$3M-Abingdon Health completed a Series B funding round on October 24, 2014. The round supported the acquisition of a 50.1% stake in diagnostics company Molecular Vision. Following the investment, Imperial Innovations held a 28.6% stake in Abingdon Health and retained a 36.4% stake in Molecular Vision.

Acquisitions by Abingdon Health

Abingdon Health has acquired 4 companies to date.

Last acquisition by Abingdon Health was on July 25th 2024. Abingdon Health acquired Compliance Solutions for $4M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Abingdon Health

Compliance Solutions
IVDeology
Molecular Vision
Serascience
Description
Compliance Solutions is a life sciences consultancy specializing in quality management systems, risk assessments, and regulatory submissions for medical devices and pharmaceuticals. The California-based firm supports ISO 13485 audits, FDA 483 responses, and EU MDR transitions through CAPA management and validation services.
-
Molecular Vision is a London-based optical detection company offering portable diagnostic devices using organic LEDs and photodetectors. Founded in 2001, its platform enables point-of-care fluorescence assays for biomarkers in blood and saliva. Applications extend to veterinary diagnostics, food safety testing for pathogens, and environmental monitoring of pollutants in field conditions.
Serascience is a UK-based diagnostic company developing assays for B-cell malignancies like multiple myeloma. Established in 2011, it supplies over 50 monoclonal antibodies specific to immunoglobulin classes and subclasses for applications in flow cytometry, ELISA, and immunohistochemistry. The Oxford facility produces reagents used by research labs worldwide, including heavy/light chain pairings for minimal residual disease monitoring. Serascience collaborates with NHS trusts on prognostic tools enhancing patient stratification in clinical trials.
HQ CountryUnited StatesUnited KingdomUnited KingdomUnited Kingdom
HQ City
-
-
London
Nottingham
Deal Date25 Jul 20247 May 20248 Jan 201524 Oct 2014
Valuation$4M$1Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Abingdon Health acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Abingdon Health

When was Abingdon Health founded?Abingdon Health was founded in 2008.
Where is Abingdon Health headquartered?Abingdon Health is headquartered in United Kingdom.
How many employees does Abingdon Health have?As of today, Abingdon Health has over 121 employees.
Is Abingdon Health publicly listed?Yes, Abingdon Health is a public company listed on London Stock Exchange.
What is the stock symbol of Abingdon Health?Abingdon Health trades under ABDX ticker.
When did Abingdon Health go public?Abingdon Health went public in 2020.
Who are competitors of Abingdon Health?Abingdon Health main competitors include NanoRepro, InspireMD, TELA Bio, Bioretec, Q-linea, Baird Medical Investment, BrainCool, Spirit Scientific Co, Cleo Diagnostics, OncoSil Medical.
What is the current market cap of Abingdon Health?Abingdon Health's current market cap is $33M.
What is the current revenue of Abingdon Health?Abingdon Health's last 12 months revenue is $17M.
What is the current revenue growth of Abingdon Health?Abingdon Health revenue growth (NTM/LTM) is 23%.
What is the current EV/Revenue multiple of Abingdon Health?Current revenue multiple of Abingdon Health is 1.8x.
Is Abingdon Health profitable?No, Abingdon Health is not profitable.
What is the current EBITDA of Abingdon Health?Abingdon Health has negative EBITDA and is not profitable.
What is Abingdon Health's EBITDA margin?Abingdon Health's last 12 months EBITDA margin is (7%).
What is the current EV/EBITDA multiple of Abingdon Health?Current EBITDA multiple of Abingdon Health is (23.8x).
How many companies Abingdon Health has acquired to date?As of July 2026, Abingdon Health has acquired 4 companies.
What was the largest acquisition by Abingdon Health?$4M acquisition of Compliance Solutions on 25th July 2024 was the largest M&A Abingdon Health has done to date.
What companies Abingdon Health acquired?Abingdon Health acquired Compliance Solutions, IVDeology, Serascience, and Molecular Vision.
In how many companies Abingdon Health has invested to date?Abingdon Health hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Abingdon Health

Lists including Abingdon Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial